title: Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity.
abstract: Vaccines are among the most effective approaches to prevent and control many infectious diseases. Because of safety and reproducibility concerns, whole-cell vaccines (WCVs), made from live or killed microorganisms and including hundreds of antigenic components, have been mostly replaced by acellular or subunit vaccines composed of well-defined, purified antigen components. The efficacy of acellular vaccines is inferior to that of WCVs, however, for two major reasons: limited antigen diversity and reduced immunogenicity, especially in a lack of activation of antigen-specific T-cell immunity, which plays an important role in protection against mucosal and intracellular pathogens. Here we present the multiple antigen-presenting system (MAPS), which enables the creation of a macromolecular complex that mimics the properties of WCVs by integrating various antigen components, including polysaccharides and proteins, in the same construct and that induces multipronged immune responses, including antibody, Th1, and Th17 responses. Using antigens from various pathogens (Streptococcus pneumoniae, Salmonella typhi, and Mycobacterium tuberculosis), we demonstrate the versatility of the MAPS system and its feasibility for the design of unique defined-structure subunit vaccines to confer comprehensive protection via multiple immune mechanisms. Moreover, MAPS can serve as a tool for structure-activity analysis of cellular immunogens.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
authors.forename: Fan
authors.initials: F
authors.lastname: Zhang
authors.forename: Ying-Jie
authors.initials: YJ
authors.lastname: Lu
authors.forename: Richard
authors.initials: R
authors.lastname: Malley
mesh_terms: D017951:Antigen Presentation / Q000276:immunology*; D000942:Antigens, Bacterial / Q000276:immunology*; D015195:Drug Design; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology*; D046911:Macromolecular Substances / Q000276:immunology*; D009169:Mycobacterium tuberculosis / Q000276:immunology; D012485:Salmonella typhi / Q000276:immunology; D013296:Streptococcus pneumoniae / Q000276:immunology; D013329:Structure-Activity Relationship; D022282:Vaccines, Acellular / Q000276:immunology*
chemical_list: D000942:Antigens, Bacterial; D046911:Macromolecular Substances; D022282:Vaccines, Acellular
references.citation: PLoS One. 2012;7(8):e43445
references.pmid: 22905267
references.citation: Methods. 2006 Sep;40(1):1-9
references.pmid: 16997708
references.citation: J Infect Dis. 1985 Sep;152(3):634-6
references.pmid: 3875668
references.citation: J Immunol. 1986 Apr 1;136(7):2348-57
references.pmid: 2419430
references.citation: Vaccine. 2010 Nov 3;28(47):7468-75
references.pmid: 20858450
references.citation: J Mol Med (Berl). 2010 Feb;88(2):135-42
references.pmid: 20049411
references.citation: Cytokine Growth Factor Rev. 2010 Dec;21(6):443-8
references.pmid: 21095154
references.citation: Vaccine. 2010 Apr 19;28(18):3071-5
references.pmid: 20206671
references.citation: Infect Immun. 1999 Feb;67(2):981-5
references.pmid: 9916120
references.citation: Nat Immunol. 2007 Apr;8(4):369-77
references.pmid: 17351619
references.citation: J Immunol. 2011 Sep 1;187(5):2278-90
references.pmid: 21775683
references.citation: Nat Rev Microbiol. 2011 Oct 03;9(12):889-93
references.pmid: 21963800
references.citation: J Clin Invest. 2010 May;120(5):1762-73
references.pmid: 20364087
references.citation: Infect Immun. 2006 Apr;74(4):2187-95
references.pmid: 16552049
references.citation: J R Soc Interface. 2007 Oct 22;4(16):787-802
references.pmid: 17426010
references.citation: N Engl J Med. 2013 Feb 7;368(6):583-4
references.pmid: 23388024
references.citation: Curr Opin Immunol. 2011 Jun;23(3):407-13
references.pmid: 21514128
references.citation: J Antimicrob Chemother. 1986 Jul;18 Suppl A:35-45
references.pmid: 3745031
references.citation: Annu Rev Immunol. 2007;25:821-52
references.pmid: 17201677
references.citation: Lancet. 1998 Jan 31;351(9099):356-61
references.pmid: 9652634
references.citation: Trends Immunol. 2009 Jan;30(1):23-32
references.pmid: 19059004
references.citation: Vaccine. 1998 Jan;16(1):83-91
references.pmid: 9607014
references.citation: Nature. 2006 Apr 6;440(7085):808-12
references.pmid: 16489357
references.citation: Arthritis Res Ther. 2012 Mar 14;14(2):R64
references.pmid: 22417709
references.citation: Microb Pathog. 1987 Oct;3(4):249-60
references.pmid: 2462151
references.citation: Semin Immunol. 2007 Dec;19(6):377-82
references.pmid: 18054248
references.citation: J Infect Dis. 1981 Dec;144(6):509-20
references.pmid: 6977001
references.citation: Immunol Cell Biol. 2004 Oct;82(5):488-96
references.pmid: 15479434
references.citation: Cell Mol Life Sci. 2008 Oct;65(20):3231-40
references.pmid: 18668203
references.citation: Infect Immun. 1996 Dec;64(12):5255-62
references.pmid: 8945574
references.citation: Biochem J. 2007 Aug 1;405(3):397-405
references.pmid: 17447892
references.citation: Lancet. 2011 Dec 3;378(9807):1962-73
references.pmid: 21492929
references.citation: PLoS Pathog. 2012;8(5):e1002607
references.pmid: 22589713
references.citation: J Immunol. 2005 Jul 15;175(2):788-95
references.pmid: 16002675
references.citation: Nat Med. 2011 Nov 20;17(12):1602-9
references.pmid: 22101769